All In MedTech

FDA Clearance Tracker · P170011-S035

Impella RP System, Impella RP with SmartAssist System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 19, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 19, 2022

Approved

Time to decision

257 days

Received Aug 5, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P170011-S035
Device name
Impella RP System, Impella RP with SmartAssist System
Applicant
Abiomed, Inc.
Applicant location
Danvers, MA
Received
Aug 5, 2021
Decided
Apr 19, 2022
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P170011

Device type

Device class
Class III
Regulation
21 CFR 870.4360
Specialty
Cardiology

Every decision under product code PYX

FDA's approval statement

As written in FDA's record.

Approval for revising the Instructions for Use to allow the use of sodium bicarbonate (25 or 50 mEq/L) as an alternative to heparin (25 or 50 U/mL) in the purge fluid during clinical use of the Impella catheters in patients intolerant to heparin or in whom heparin is contraindicated.

Source documents

Other decisions for Abiomed, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.